Kura Sushi to Reproduce Representative Dishes of 70 Countries and Regions Participating in the Osaka-Kansai Expo!
12.12.2024 02:00:00 CET | Business Wire | Press release
70 Expo Special Menu Items UnveiledAntibacterial Sushi Covers with Expo-specific Designs Also Available
Kura Sushi Inc. (Headquarters: Sakai City, Osaka Prefecture), one of the world’s most popular conveyor-belt sushi chains, announced on December 12 that it will offer 70 new menu items at its restaurant that will open at the “Osaka-Kansai Expo,” which will open on April 13 next year in Yumeshima, Osaka, featuring dishes representing 70 countries and regions scheduled to participate in the Expo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211605079/en/
Antibacterial Sushi Covers with Expo-specific Designs (Photo: Business Wire)
The company is the only major revolving sushi chain in Japan to serve sushi on conveyor belts at all of its restaurants. Under the concept of “Revolving Belts Unite the World,” the company will open a restaurant at the Osaka-Kansai Expo with 338 seats, the most in the company’s history, and a revolving belt about 135 meters long, the longest in the company’s history.
With the intention to bring smiles to the faces of visitors from all over the world and provide them with an enjoyable dining experience, the “Hands・Hands Project,” a project that will offer a special 70 Expo menu representing each country and region scheduled to participate in the Expo, will be launched. The menu has been developed by the company’s product development team. The company’s product development team have been working on these menu items with a focus on reproducing the authentic flavors of the countries and regions. Twenty-four of the items have been recreated after being tasted and advised on by ambassadors and other people from these countries under the collaboration with each embassy.
In addition, the antibacterial sushi cover “Mr. Freshness,” which is being used for this special menu, has been specially designed with the connecting part appearing as red and blue hands shaking, the signature colors of the Expo. By serving the special menu side by side with the company’s popular sushi menu, sushi and dishes from different countries and regions flow hand in hand in front of the customers. Along with enjoying their meal, guests will be able to enjoy the experience as if they were visiting a pavilion that explores the culinary cultures of countries around the world.
To help building momentum for the Expo, special Expo menus will be offered ahead of time at about 550 restaurants nationwide, starting on February 7, 2025 (Friday). Each store will offer one item from a menu of 70 different items, as if each store were a “mini-pavilion” where visitors can enjoy the flavors of the respective country. As every neighborhood store will offer a different menu item from a different country or region, customers will be able to enjoy the menu at their local Kura Sushi restaurants, or they can enjoy all 70 items on the Expo special menu by visiting different Kura Sushi restaurants in Japan.
Kaitenzushi (Revolving Sushi Restaurant) is said to have spread throughout Japan after attracting attention at the Osaka Expo in 1970. Since then, Kaitenzushi has steadily expanded its market size while evolving in various ways over its 50-year history, and is now a leading business category in the evolution of the Japanese food service industry, with sales exceeding 800 billion yen. Going forward, the company will continue to leverage its strength, the revolving belt, to provide customers in Japan and overseas with the memorable enjoyment that only Kura Sushi can offer, thereby expanding the revolving sushi business model, a wonderful business model that originated in Japan, to the entire world.
Mr. Makoto Tanaka, Executive Vice President of Kura Sushi, held a press conference on the day of the event, and mentioned, “These days, the world is filled with a variety of social issues that are difficult to solve. Even under such circumstances, we hope that the conveyor-belt sushi restaurants, which are connected by a “conveyor belt that has no beginning and no end,” will unite people from all over the world who visit the Expo to have an enjoyable dining experience with a smile on their faces. We hope that visitors from all over the world, including Japanese customers, as well as tourists from all over the world, will enjoy the menu which we have created with the combined efforts of our Product Development Division to recreate the authentic flavors of the world.”
As of the end of November, Kura Sushi Inc. operates 547 restaurants in Japan, 70 in the United States, 59 in Taiwan, and 3 in Shanghai.
Check out our other products here. https://www.kurasushi.co.jp/2025expo/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211605079/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom